<DOC>
	<DOCNO>NCT01758965</DOCNO>
	<brief_summary>The aim study assess effect Surgicel® Fibrillar adjuvant treatment H2RA prevent ulcer bleed ESD gastric epithelial tumor</brief_summary>
	<brief_title>Surgicel® Fibrillar Delayed Bleeding After ESD</brief_title>
	<detailed_description>1 . Patient ( 1 ) Inclusion : Diagnosed gastric dysplasia early gastric cancer - Scheduled ESD ( 2 ) Exclusion : Coagulopathy- liver cirrhosis , thrombocytopenia - Anti-platelet agent 2 . Method ( 1 ) Study group : combination Surgicel® Fibrillar H2RA ( 2 ) Control group : monotherapy PPI 3 . Sample size : 157 4 . Result 1 . Primary endpoint : rate delay bleed ESD 2 . Secondary endpoint : follow-up hemoglobin ESD</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>ESD gastric dysplasia early gastric cancer Coagulopathy : liver cirrhosis , thrombocytopenia Antiplatelet agent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>